• Tweet

NeoPharm (NEOL.PK), a biopharmaceutical company developing drugs for cancer treatment, has been tipped as a worthwhile stock on financial website Seeking Alpha. The writer cited the stock’s low cost and the company’s impressive cancer-fighting pipeline as reasons to invest. NeoPharm is “loaded with potential and flying under the radar,” he writes.

Laurence P. Birch, President and CEO of NeoPharm, agrees. Birch states, “In the last several years, with the help of Dr. Aquil Rahman, one of its founders who has returned to the company, NeoPharm has transformed itself from a bloated company with one large failed trial, to a nimble company with several promising drugs in various stages of clinical development—a very exciting time, for sure.”

NeoPharm is engaged in the research, development and commercialization of new drugs for various cancers and other diseases. The company focuses on two key areas of development: tumor targeting and drug delivery. NeoPharm’s tumor-targeting system aims to destroy cancerous cells while preserving healthy tissue. The NeoLipid drug delivery platform entraps difficult-to-deliver drugs in liposomes, which are small, membrane-like structures created from fats. Because tumor cells need to consume large amounts of fat to sustain their rapid growth, they recognize the liposomal drug as a potential source of nutrition. Products in NeoPharm’s pipeline include drug candidates for brain cancer, breast cancer, pancreatic cancer, idiopathic pulmonary fibrosis, and asthma.